Eledon Pharmaceuticals, Inc (ELDN) - Koefisien utang jangka dawa marang modal

Eledon Pharmaceuticals (ELDN) business risks are tied to the trial results of anti-rejection therapies and pressure from traditional treatment methods. The price action on GURU.Markets for the separate_debt_long_eq metric stands at 0.00. US laboratories developing immunological innovations ensure the company's stability. Independence from global economic fluctuations and steady demand for biotechnology turn the asset into a high-quality defensive tool.

Strong liquidity and the management competencies of Eledon Pharmaceuticals (ELDN) in immunological biotech drive the stable dynamics of the long-term debt-to-equity ratio. This ratio, calculated as long-term liabilities divided by total equity, measures the company's financial leverage; its low values confirm independent development and risk minimization through effective management of borrowed capital.